{"entity":"novo-nordisk","id":"ent_novo-nordisk","name":"Novo Nordisk","wikidata":"Q818846","page":"https://asof.is/record/novo-nordisk","summary":"Novo Nordisk is a Danish pharmaceutical company, headquartered in Bagsvaerd Denmark. Its CEO is Maziar Mike Doustdar, since 2025. It reported revenue of 309.06B DKK for the period ended December 31, 2025.","title":"Novo Nordisk: CEO Maziar Mike Doustdar","key_facts":[{"label":"CEO","value":"Maziar Mike Doustdar","note":"since 2025","claim":"clm_09DBC29C37EF"},{"label":"Chair","value":"Lars Rebien Sørensen","claim":"clm_572A7A46A90E"},{"label":"Headquarters","value":"Bagsvaerd Denmark","claim":"clm_71389B010ACD"},{"label":"Revenue","value":"309.06B DKK","recorded":"309,064,000,000 DKK","note":"to 2025-12-31","claim":"clm_8F7EC31D7FFC"},{"label":"Employees","value":"69,505 employee","note":"as of 2025-12-31","claim":"clm_8EB909BEF688"},{"label":"Ticker","value":"NVO · NYSE","claim":"clm_A89E46223B59"}],"faq":[{"question":"Who is the CEO of Novo Nordisk?","answer":"Maziar Mike Doustdar, since 2025, as the AsOf record states with its sources."},{"question":"Where is Novo Nordisk headquartered?","answer":"Bagsvaerd Denmark."},{"question":"What is Novo Nordisk's revenue?","answer":"309.06B DKK for the period ended December 31, 2025."}],"as_of":null,"known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/novo-nordisk/ceo","md":"https://asof.is/record/novo-nordisk/ceo.md","json":"https://asof.is/v1/entities/novo-nordisk/ceo"},{"predicate":"chair","page":"https://asof.is/record/novo-nordisk/chair","md":"https://asof.is/record/novo-nordisk/chair.md","json":"https://asof.is/v1/entities/novo-nordisk/chair"},{"predicate":"headquarters","page":"https://asof.is/record/novo-nordisk/headquarters","md":"https://asof.is/record/novo-nordisk/headquarters.md","json":"https://asof.is/v1/entities/novo-nordisk/headquarters"},{"predicate":"employees","page":"https://asof.is/record/novo-nordisk/employees","md":"https://asof.is/record/novo-nordisk/employees.md","json":"https://asof.is/v1/entities/novo-nordisk/employees"},{"predicate":"revenue","page":"https://asof.is/record/novo-nordisk/revenue","md":"https://asof.is/record/novo-nordisk/revenue.md","json":"https://asof.is/v1/entities/novo-nordisk/revenue"},{"predicate":"net_income","page":"https://asof.is/record/novo-nordisk/net_income","md":"https://asof.is/record/novo-nordisk/net_income.md","json":"https://asof.is/v1/entities/novo-nordisk/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/novo-nordisk/operating_income","md":"https://asof.is/record/novo-nordisk/operating_income.md","json":"https://asof.is/v1/entities/novo-nordisk/operating_income"}],"products":[],"coverage":{"entity":"novo-nordisk","name":"Novo Nordisk","kind":"organization","sources":[{"source":"wikidata","item":"Q818846","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":353278,"ticker":"NVO","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":55,"open":19,"retracted":0,"first":"1923-01-01","predicates":{"listed_on":{"claims":2,"open":2,"kind":"fact"},"total_assets":{"claims":6,"open":1,"kind":"fact"},"ceo":{"claims":1,"open":1,"kind":"fact"},"operating_income":{"claims":7,"open":1,"kind":"fact"},"net_income":{"claims":7,"open":1,"kind":"fact"},"total_equity":{"claims":8,"open":1,"kind":"fact"},"employees":{"claims":7,"open":1,"kind":"fact"},"ticker":{"claims":2,"open":2,"kind":"identifier"},"revenue":{"claims":7,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"chair":{"claims":1,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":53,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":2,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_51EBABE50856","predicate":"total_equity","value":"194,047,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 194,047,000,000 DKK\", as of 2025-12-31. Claim clm_51EBABE50856, https://asof.is/claim/clm_51EBABE50856, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_51EBABE50856","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_672756B8F8A9","predicate":"operating_income","value":"127,658,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 127,658,000,000 DKK\", as of 2025-12-31. Claim clm_672756B8F8A9, https://asof.is/claim/clm_672756B8F8A9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_672756B8F8A9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_8EB909BEF688","predicate":"employees","value":"69,505 employee","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 69,505 employee\", as of 2025-12-31. Claim clm_8EB909BEF688, https://asof.is/claim/clm_8EB909BEF688, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8EB909BEF688","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"},{"url":"https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0","tier":"secondary","publisher":null,"published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_8F7EC31D7FFC","predicate":"revenue","value":"309,064,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 309,064,000,000 DKK\", as of 2025-12-31. Claim clm_8F7EC31D7FFC, https://asof.is/claim/clm_8F7EC31D7FFC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8F7EC31D7FFC","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_BCB17EC648AA","predicate":"total_assets","value":"542,902,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 542,902,000,000 DKK\", as of 2025-12-31. Claim clm_BCB17EC648AA, https://asof.is/claim/clm_BCB17EC648AA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_BCB17EC648AA","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_F536BDE429B7","predicate":"net_income","value":"102,434,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 102,434,000,000 DKK\", as of 2025-12-31. Claim clm_F536BDE429B7, https://asof.is/claim/clm_F536BDE429B7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_F536BDE429B7","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_09DBC29C37EF","predicate":"ceo","value":"Maziar Mike Doustdar","valid_from":"2025-08-07","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ceo: Maziar Mike Doustdar\", as of 2025-08-07. Claim clm_09DBC29C37EF, https://asof.is/claim/clm_09DBC29C37EF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm.","url":"https://asof.is/claim/clm_09DBC29C37EF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","tier":"primary","publisher":"SEC EDGAR 20-F","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"On 7 August 2025, Maziar Mike Doustdar succeeded Lars Fruergaard Jørgensen as president and chief executive officer of Novo Nordisk.","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm"}},{"id":"clm_109041F6F3C0","predicate":"operating_income","value":"128,339,000,000 DKK","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 128,339,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_109041F6F3C0, https://asof.is/claim/clm_109041F6F3C0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_109041F6F3C0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_672756B8F8A9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_36763BC50C4E","predicate":"total_assets","value":"465,795,000,000 DKK","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 465,795,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_36763BC50C4E, https://asof.is/claim/clm_36763BC50C4E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_36763BC50C4E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BCB17EC648AA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_4145313CD790","predicate":"total_equity","value":"143,486,000,000 DKK","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 143,486,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_4145313CD790, https://asof.is/claim/clm_4145313CD790, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_4145313CD790","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_51EBABE50856","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_6A7CC2B7840B","predicate":"employees","value":"77,349 employee","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 77,349 employee\", as of 2024-12-31 (until 2025-12-31). Claim clm_6A7CC2B7840B, https://asof.is/claim/clm_6A7CC2B7840B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_6A7CC2B7840B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8EB909BEF688","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_8A5C5EE097FD","predicate":"net_income","value":"100,988,000,000 DKK","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 100,988,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_8A5C5EE097FD, https://asof.is/claim/clm_8A5C5EE097FD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_8A5C5EE097FD","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F536BDE429B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_A3B9347CE850","predicate":"revenue","value":"290,403,000,000 DKK","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 290,403,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_A3B9347CE850, https://asof.is/claim/clm_A3B9347CE850, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_A3B9347CE850","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8F7EC31D7FFC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2024, filed 2025-02-05"}},{"id":"clm_5B1E4C20C74E","predicate":"employees","value":"64,319 employee","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 64,319 employee\", as of 2023-12-31 (until 2024-12-31). Claim clm_5B1E4C20C74E, https://asof.is/claim/clm_5B1E4C20C74E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_5B1E4C20C74E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A7CC2B7840B","sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"},{"url":"https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_792EA3966BEF","predicate":"operating_income","value":"102,574,000,000 DKK","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 102,574,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_792EA3966BEF, https://asof.is/claim/clm_792EA3966BEF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_792EA3966BEF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_109041F6F3C0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_8ED842A2DCE7","predicate":"revenue","value":"232,261,000,000 DKK","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 232,261,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_8ED842A2DCE7, https://asof.is/claim/clm_8ED842A2DCE7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_8ED842A2DCE7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A3B9347CE850","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_A36685A1C540","predicate":"total_assets","value":"314,486,000,000 DKK","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 314,486,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A36685A1C540, https://asof.is/claim/clm_A36685A1C540, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A36685A1C540","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_36763BC50C4E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_A40D8D2F280A","predicate":"total_equity","value":"106,561,000,000 DKK","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 106,561,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A40D8D2F280A, https://asof.is/claim/clm_A40D8D2F280A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A40D8D2F280A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4145313CD790","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_A49F4F076521","predicate":"net_income","value":"83,683,000,000 DKK","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 83,683,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A49F4F076521, https://asof.is/claim/clm_A49F4F076521, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A49F4F076521","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8A5C5EE097FD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-01-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2023, filed 2024-01-31"}},{"id":"clm_1A208DF6F487","predicate":"net_income","value":"55,525,000,000 DKK","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 55,525,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_1A208DF6F487, https://asof.is/claim/clm_1A208DF6F487, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_1A208DF6F487","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A49F4F076521","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_459BEEC0AB43","predicate":"revenue","value":"176,954,000,000 DKK","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 176,954,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_459BEEC0AB43, https://asof.is/claim/clm_459BEEC0AB43, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_459BEEC0AB43","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8ED842A2DCE7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_56708B41C767","predicate":"total_assets","value":"241,257,000,000 DKK","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 241,257,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_56708B41C767, https://asof.is/claim/clm_56708B41C767, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_56708B41C767","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A36685A1C540","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_800F88E2D840","predicate":"total_equity","value":"83,486,000,000 DKK","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 83,486,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_800F88E2D840, https://asof.is/claim/clm_800F88E2D840, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_800F88E2D840","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A40D8D2F280A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_D62CD294DD73","predicate":"employees","value":"55,185 employee","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 55,185 employee\", as of 2022-12-31 (until 2023-12-31). Claim clm_D62CD294DD73, https://asof.is/claim/clm_D62CD294DD73, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_D62CD294DD73","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B1E4C20C74E","sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"},{"url":"https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2023/novo-nordisk-annual-report-2022.pdf","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_F3418E0D3161","predicate":"operating_income","value":"74,809,000,000 DKK","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 74,809,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_F3418E0D3161, https://asof.is/claim/clm_F3418E0D3161, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_F3418E0D3161","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_792EA3966BEF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2022, filed 2023-02-01"}},{"id":"clm_1B204B243A08","predicate":"total_equity","value":"70,746,000,000 DKK","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 70,746,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_1B204B243A08, https://asof.is/claim/clm_1B204B243A08, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_1B204B243A08","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_800F88E2D840","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_4E462623C749","predicate":"operating_income","value":"58,644,000,000 DKK","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 58,644,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_4E462623C749, https://asof.is/claim/clm_4E462623C749, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_4E462623C749","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F3418E0D3161","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_6D30A77C658F","predicate":"total_assets","value":"194,508,000,000 DKK","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 194,508,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_6D30A77C658F, https://asof.is/claim/clm_6D30A77C658F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_6D30A77C658F","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56708B41C767","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_71916DF751CE","predicate":"employees","value":"48,478 employee","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 48,478 employee\", as of 2021-12-31 (until 2022-12-31). Claim clm_71916DF751CE, https://asof.is/claim/clm_71916DF751CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_71916DF751CE","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D62CD294DD73","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_8F5ADB2C07ED","predicate":"net_income","value":"47,757,000,000 DKK","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 47,757,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_8F5ADB2C07ED, https://asof.is/claim/clm_8F5ADB2C07ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_8F5ADB2C07ED","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1A208DF6F487","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_DEF63B463032","predicate":"revenue","value":"140,800,000,000 DKK","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 140,800,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_DEF63B463032, https://asof.is/claim/clm_DEF63B463032, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_DEF63B463032","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_459BEEC0AB43","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_072CD0878EE5","predicate":"total_assets","value":"144,922,000,000 DKK","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 144,922,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_072CD0878EE5, https://asof.is/claim/clm_072CD0878EE5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_072CD0878EE5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D30A77C658F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_2112055E65B9","predicate":"net_income","value":"42,138,000,000 DKK","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 42,138,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_2112055E65B9, https://asof.is/claim/clm_2112055E65B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_2112055E65B9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8F5ADB2C07ED","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_5D92621F8B64","predicate":"employees","value":"45,323 employee","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 45,323 employee\", as of 2020-12-31 (until 2021-12-31). Claim clm_5D92621F8B64, https://asof.is/claim/clm_5D92621F8B64, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_5D92621F8B64","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71916DF751CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_67D64D48F06E","predicate":"revenue","value":"126,946,000,000 DKK","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 126,946,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_67D64D48F06E, https://asof.is/claim/clm_67D64D48F06E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_67D64D48F06E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DEF63B463032","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_D272A9AE2D76","predicate":"operating_income","value":"54,126,000,000 DKK","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 54,126,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_D272A9AE2D76, https://asof.is/claim/clm_D272A9AE2D76, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_D272A9AE2D76","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4E462623C749","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_D44DDD0D515C","predicate":"total_equity","value":"63,325,000,000 DKK","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 63,325,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_D44DDD0D515C, https://asof.is/claim/clm_D44DDD0D515C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_D44DDD0D515C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B204B243A08","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_277344156E80","predicate":"employees","value":"43,258 employee","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 43,258 employee\", as of 2019-12-31 (until 2020-12-31). Claim clm_277344156E80, https://asof.is/claim/clm_277344156E80, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_277344156E80","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5D92621F8B64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_43C7BF9EE087","predicate":"total_equity","value":"57,593,000,000 DKK","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 57,593,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_43C7BF9EE087, https://asof.is/claim/clm_43C7BF9EE087, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_43C7BF9EE087","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D44DDD0D515C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_B2B75C38DC99","predicate":"operating_income","value":"52,483,000,000 DKK","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 52,483,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_B2B75C38DC99, https://asof.is/claim/clm_B2B75C38DC99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_B2B75C38DC99","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D272A9AE2D76","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_DA4855A5F51A","predicate":"net_income","value":"38,951,000,000 DKK","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 38,951,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_DA4855A5F51A, https://asof.is/claim/clm_DA4855A5F51A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_DA4855A5F51A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2112055E65B9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_F0275DE8A21D","predicate":"revenue","value":"122,021,000,000 DKK","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 122,021,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_F0275DE8A21D, https://asof.is/claim/clm_F0275DE8A21D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_F0275DE8A21D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_67D64D48F06E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_3322844F3158","predicate":"total_equity","value":"51,839,000,000 DKK","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 51,839,000,000 DKK\", as of 2018-12-31 (until 2019-12-31). Claim clm_3322844F3158, https://asof.is/claim/clm_3322844F3158, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_3322844F3158","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_43C7BF9EE087","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"id":"clm_C639BE305784","predicate":"x_username","value":"novonordisk","valid_from":"2010-09-23","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk x username: novonordisk\", as of 2010-09-23. Claim clm_C639BE305784, https://asof.is/claim/clm_C639BE305784, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q818846.","url":"https://asof.is/claim/clm_C639BE305784","accessed":"2026-11-10"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/novonordisk","url":"https://www.novonordisk.com"}},{"id":"clm_F171E5861BC9","predicate":"website","value":"https://www.novonordisk.com","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk website: https://www.novonordisk.com\", undated. Claim clm_F171E5861BC9, https://asof.is/claim/clm_F171E5861BC9, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q818846.","url":"https://asof.is/claim/clm_F171E5861BC9","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Novo Nordisk.","url":"https://www.novonordisk.com"}},{"id":"clm_07286C13C782","predicate":"listed_on","value":"OTC","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk listed on: OTC\", undated. Claim clm_07286C13C782, https://asof.is/claim/clm_07286C13C782, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_07286C13C782","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2B51766EA897","predicate":"ticker","value":"NONOF","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ticker: NONOF\", undated. Claim clm_2B51766EA897, https://asof.is/claim/clm_2B51766EA897, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_2B51766EA897","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_52574002BF9D","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_52574002BF9D, https://asof.is/claim/clm_52574002BF9D, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_52574002BF9D","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_52A9D25B5082","predicate":"cik","value":"0000353278","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk cik: 0000353278\", undated. Claim clm_52A9D25B5082, https://asof.is/claim/clm_52A9D25B5082, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_52A9D25B5082","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_572A7A46A90E","predicate":"chair","value":"Lars Rebien Sørensen","valid_from":null,"undated":true,"valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk chair: Lars Rebien Sørensen\", undated. Claim clm_572A7A46A90E, https://asof.is/claim/clm_572A7A46A90E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm.","url":"https://asof.is/claim/clm_572A7A46A90E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","tier":"primary","publisher":"SEC EDGAR 20-F","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"The chair of the Foundation’s board of directors (Lars Rebien Sørensen) serves as the chair of Novo Nordisk A/S’ board of directors.","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm"}},{"id":"clm_5C5C98A60302","predicate":"registrant_name","value":"NOVO NORDISK A S","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk registrant name: NOVO NORDISK A S\", undated. Claim clm_5C5C98A60302, https://asof.is/claim/clm_5C5C98A60302, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_5C5C98A60302","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_71389B010ACD","predicate":"headquarters","value":"Bagsvaerd Denmark","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk headquarters: Bagsvaerd Denmark\", undated. Claim clm_71389B010ACD, https://asof.is/claim/clm_71389B010ACD, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_71389B010ACD","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A875D9470529","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk fiscal year end: 12-31\", undated. Claim clm_A875D9470529, https://asof.is/claim/clm_A875D9470529, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_A875D9470529","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A89E46223B59","predicate":"ticker","value":"NVO","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ticker: NVO\", undated. Claim clm_A89E46223B59, https://asof.is/claim/clm_A89E46223B59, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_A89E46223B59","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_AECDFCB7C547","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk listed on: NYSE\", undated. Claim clm_AECDFCB7C547, https://asof.is/claim/clm_AECDFCB7C547, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_AECDFCB7C547","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it.","low_confidence":"Confidence below 0.5, the line the record asserts at."},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}